These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 25773722)

  • 21. Backgrounded Membrane Imaging (BMI) for High-Throughput Characterization of Subvisible Particles During Biopharmaceutical Drug Product Development.
    Helbig C; Ammann G; Menzen T; Friess W; Wuchner K; Hawe A
    J Pharm Sci; 2020 Jan; 109(1):264-276. PubMed ID: 30914272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controlled polysorbate 20 hydrolysis - A new approach to assess the impact of polysorbate 20 degradation on biopharmaceutical product quality in shortened time.
    Graf T; Abstiens K; Wedekind F; Elger C; Haindl M; Wurth C; Leiss M
    Eur J Pharm Biopharm; 2020 Jul; 152():318-326. PubMed ID: 32445968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of Subvisible Particles in Biotherapeutic Prefilled Syringes: The Role of Polysorbate and Protein on the Formation of Silicone Oil and Protein Subvisible Particles After Drop Shock.
    Jiao N; Barnett GV; Christian TR; Narhi LO; Joh NH; Joubert MK; Cao S
    J Pharm Sci; 2020 Jan; 109(1):640-645. PubMed ID: 31689431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The degradation of polysorbates 20 and 80 and its potential impact on the stability of biotherapeutics.
    Kishore RS; Kiese S; Fischer S; Pappenberger A; Grauschopf U; Mahler HC
    Pharm Res; 2011 May; 28(5):1194-210. PubMed ID: 21369824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring polysorbate hydrolysis in biopharmaceuticals using a QC-ready free fatty acid quantification method.
    Honemann MN; Wendler J; Graf T; Bathke A; Bell CH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 May; 1116():1-8. PubMed ID: 30951966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced Subvisible Particle Formation in Lyophilized Intravenous Immunoglobulin Formulations Containing Polysorbate 20.
    Zhou C; Qi W; Lewis EN; Randolph TW; Carpenter JF
    J Pharm Sci; 2016 Aug; 105(8):2302-9. PubMed ID: 27290624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stress-mediated polysorbate 20 degradation and its potential impact on therapeutic proteins.
    Aryal B; Lehtimaki M; Rao VA
    Pharm Res; 2024 Jun; 41(6):1217-1232. PubMed ID: 38740663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metal-Induced Fatty Acid Particle Formation Resulting from Hydrolytic Polysorbate Degradation.
    Gregoritza K; Cai SK; Siketanc M; Woehr A; Lebouc V; Kishore RSK; Nicoulin V; Bleher S; Allmendinger A
    J Pharm Sci; 2022 Mar; 111(3):743-751. PubMed ID: 34600939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An in-depth examination of fatty acid solubility limits in biotherapeutic protein formulations containing polysorbate 20 and polysorbate 80.
    Glücklich N; Dwivedi M; Carle S; Buske J; Mäder K; Garidel P
    Int J Pharm; 2020 Dec; 591():119934. PubMed ID: 33059015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Rapid High-Sensitivity Reversed-Phase Ultra High Performance Liquid Chromatography Mass Spectrometry Method for Assessing Polysorbate 20 Degradation in Protein Therapeutics.
    Cheng Y; Hu M; Zamiri C; Carcelen T; Demeule B; Tomlinson A; Gu J; Yigzaw Y; Kalo M; Yu XC
    J Pharm Sci; 2019 Sep; 108(9):2880-2886. PubMed ID: 31054888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating a Modified High Purity Polysorbate 20 Designed to Reduce the Risk of Free Fatty Acid Particle Formation.
    Doshi N; Ritchie K; Shobha T; Giddings J; Gregoritza K; Taing R; Rumbelow S; Chu J; Tomlinson A; Kannan A; Saggu M; Cai SK; Nicoulin V; Liu W; Russell S; Luis L; Yadav S
    Pharm Res; 2021 Sep; 38(9):1563-1583. PubMed ID: 34495486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polysorbate degradation in biotherapeutic formulations: Identification and discussion of current root causes.
    Dwivedi M; Blech M; Presser I; Garidel P
    Int J Pharm; 2018 Dec; 552(1-2):422-436. PubMed ID: 30300706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How enzymatic hydrolysis of polysorbate 20 influences colloidal protein stability.
    Glücklich N; Carle S; Diederichs T; Buske J; Mäder K; Garidel P
    Eur J Pharm Sci; 2023 Dec; 191():106597. PubMed ID: 37770006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Polysorbate 80 Hydrolysis and Oxidation on the Aggregation of a Monoclonal Antibody.
    Larson NR; Wei Y; Prajapati I; Chakraborty A; Peters B; Kalonia C; Hudak S; Choudhary S; Esfandiary R; Dhar P; Schöneich C; Middaugh CR
    J Pharm Sci; 2020 Jan; 109(1):633-639. PubMed ID: 31758949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization and stability study of polysorbate 20 in therapeutic monoclonal antibody formulation by multidimensional ultrahigh-performance liquid chromatography-charged aerosol detection-mass spectrometry.
    Li Y; Hewitt D; Lentz YK; Ji JA; Zhang TY; Zhang K
    Anal Chem; 2014 May; 86(10):5150-7. PubMed ID: 24749737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways.
    Kerwin BA
    J Pharm Sci; 2008 Aug; 97(8):2924-35. PubMed ID: 17973307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ester hydrolysis of polysorbate 80 in mAb drug product: evidence in support of the hypothesized risk after the observation of visible particulate in mAb formulations.
    Labrenz SR
    J Pharm Sci; 2014 Aug; 103(8):2268-77. PubMed ID: 24942482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of aggregate and silicone-oil counts in pre-filled siliconized syringes: An orthogonal study characterising the entire subvisible size range.
    Shah M; Rattray Z; Day K; Uddin S; Curtis R; van der Walle CF; Pluen A
    Int J Pharm; 2017 Mar; 519(1-2):58-66. PubMed ID: 28089934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human Serum Albumin Mitigates Formation of Fatty Acid Particles in Polysorbate-Containing Solutions.
    Kim DM; Stansberry-Perkins K; Marlow MS; Pyles EA
    J Pharm Sci; 2022 Nov; 111(11):3185-3188. PubMed ID: 35977591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Label-free flow cytometry analysis of subvisible aggregates in liquid IgG1 antibody formulations.
    Nishi H; Mathäs R; Fürst R; Winter G
    J Pharm Sci; 2014 Jan; 103(1):90-9. PubMed ID: 24218205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.